<DOC>
	<DOCNO>NCT01876823</DOCNO>
	<brief_summary>Alzheimer 's disease ( AD ) , common dementing disorder later life , major cause disability death elderly . Although number theoretical cause exist , etiology AD still unknown . Consequently , focus treatment palliative , design ameliorate AD symptom . Recent effort , however , reveal surprising data suggest cholinesterase inhibitor ( AchEIs ) , use last decade , recently release memantine ( N-methyl-D-aspartate ( NMDA ) receptor antagonist ) , may confer protection neuron . Thus , may offer slow cognitive decline and/or improvement behavioral symptom associate memory impairment . Over last decade , well document mild cognitive impairment ( MCI ) increase risk conversion AD coincident depression MCI ( Dep-MCI ) increase risk 2 3 fold . The primary focus line investigation treat high risk dement patient population Dep-MCI , develop AD , hop delay AD onset . Memantine study DEP-MCI patient . Since treatment patient combine antidepressant AChEIs associate cognitive improvement pilot study , explore whether treatment DEP-MCI memantine addition antidepressant treatment would benefit cognitive performance lead low rate conversion dementia . We evaluate cognitive antidepressant benefit combine open-label es-citalopram memantine treatment 48 week DEP-CI sample .</brief_summary>
	<brief_title>Memantine Plus Es-citalopram Elderly Depressed Patients With Cognitive Impairment</brief_title>
	<detailed_description>The study conduct sample 35 elderly ( 50-90 year old ) outpatients meet study inclusion criterion depression ( DEP ) ( DSM-IV criterion major depression , dysthymic disorder , depression NOS ) mild cognitive impairment ( MCI ; e.g . operationally defined `` normal '' `` dementia '' ) , i.e. , Dep-MCI . The research plan include : ) Obtaining baseline psychiatric neuropsychological test profile , ii ) If currently ineffective antidepressant , one week washout ( 3 week fluoxetine ) , iii ) A treatment trial begin two-week es-citalopram lead-in period . At two week , memantine ( Namenda ) add start 5 mg/day increase maximum dose 20 mg/day reach six week . The study psychiatrist administers : 24-item Hamilton Depression Rating Scale ( HAM-D ) ; Clinical Global Impression ( CGI , 1-7 scale ) initial severity subsequent change rating separately depression , cognition , overall clinical status ; Treatment Emergent Symptom Scale ( TESS ) somatic side effect . A trained technician administers neuropsychological battery baseline , 12 , 24 48 week . If patient antidepressant non-responder first 12-weeks , es-citalopram change alternative antidepressant , clinically indicate treat psychiatrist . The patient remain memantine entire 48-weeks , irrespective antidepressant response . This tell u efficacy tolerability es-citalopram+memantine cognitive depressive symptom Dep-MCI patient potentially broader public health implication Dep-MCI wide-spread clinical problem management need improve .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Of either sex , age great 49 year old 2 . Meets criteria `` depression '' `` cognitive impairment '' . 3 . Study Criteria `` depression '' : . Patients meet DSMIV criterion Major Depression , Dysthymic Disorder , Dysthymia symptoms criterion minimum 6 month duration ( 2 year DSMIV criterion ) . ii . 24item HAMD great 13 ; iii . Clinical Global Impression ( CGI ) severity Depression great 2 ( absolute score least mild moderate depression 7point scale ) 4 . Study Criteria `` cognitive deficit '' : i. Subjective memory complaint ii.Mini Mental Status Exam ( MMSE ) great 24 ; least one , b , c : 1. less 3 MMSE 5 min delay recall 2. score 2 neuropsychological test great 1 Standard Deviation ( SD ) standardize norm , 3. score 1 neuropsychological test great 2 SD standardize norm . Neuropsychological test inclusion criterion ( subset large battery ) : Selective Reminding Test delay Wechsler Memory Scale ( WMS ) : Visual Reproduction delay , % saving immed delay Controlled Oral Word Association Test Trails B Digit symbol subtest Wechsler Adult Intelligence Scale ( WAIS ) III Continuous Performance Test iii . CGI severity Cognitive deficit great 2 ( absolute score 7point scale:1=no deficit 7=severe deficit ) . iv . Clinical Dementia Rating ( CDR ) = 0 0.5 5 . Willing capable give informed consent 1 . Meets Criteria dementia ( DSMIV ) probable Alzheimer 's disease National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association criterion ( NINCDSADRDA criterion ) 2 . Meets criterion : 1. schizophrenia 2. alcohol substance dependence abuse within last 6 month . 3 . Suicidal attempt last 6 month current suicidal intent . 4 . Patients currently effective antidepressant medication 5 . Use cholinesterase inhibitor last year . 6 . Neurological disease include stroke , epilepsy , neurodegenerative disorder . 7 . An acute , severe unstable medical condition metastatic active cancer , hepatic disease , primary renal disease require dialysis . 8 . Patients tolerate taper antidepressant medication ( i.e . great 25 % incr . baseline HAMD ) history indicate patient unlikely tolerate psychotropic washout . 9 . Patient history nonresponse Citalopram escitalopram</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Memory Decline</keyword>
	<keyword>Depression</keyword>
	<keyword>Elderly</keyword>
	<keyword>Antidepressants</keyword>
	<keyword>Treatment</keyword>
	<keyword>memantine</keyword>
</DOC>